Amgen Lays Out Plans For Rare Disease Portfolio Growth

Ex-US Push, Subcutaneous Dosing For Tepezza

Amgen detailed plans for increasing sales of drugs acquired in its Horizon transaction and outlined growth opportunities in its R&D pipeline during a rare disease showcase. 

Male red plastic toy businessman silhouette wooden crowd figure background closeup
Rare disease is one of four pillars for Amgen besides general medicine, inflammation and oncology • Source: Shutterstock

Amgen, Inc. previously specialized in large therapeutic areas like cardiovascular diseases and inflammation, but added a big focus on medicines for rare diseases through its $27.8bn acquisition of Horizon Therapeutics plc last year. Now that the Horizon products and its research and development programs are in Amgen’s hands, the big biotech is going public with its plans for driving growth in rare diseases now and in the future.

Key Takeaways

  • Amgen’s rare disease portfolio generated almost $4bn in 2023 sales, almost entirely from the Horizon assets, and the company expects growth in 2024 and beyond after applying its ex-US, R&D and manufacturing expertise.

Executive vice president of global commercial operations Murdo Gordon kicked off a rare disease day that Amgen hosted for analysts...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip